Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

Novo Nordisk, maker of Ozempic and Wegovy ... Why would Trump be OK with forcing Americans to pay more than the rest of the ...

Novo Nordisk A/S (NYSE:NVO) is involved in researching, developing, producing, and distributing pharmaceutical products. Over the past year, NVO stock is down more than 20% while LLY stock has ...

The US Food and Drug Administration (FDA) has approved Novo ... other than diabetes and weight reduction, such as Alzheimer's disease and non-alcoholic steatohepatitis (NASH). Novo Nordisk ...

Novo Nordisk (NVO) closed the most recent trading day at $84.03, moving -1.36% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.47% for the day.